GA-ASI Completes Full-Scale Fatigue Test on MQ-9B for Second Lifetime
SAN DIEGO, CA / ACCESSWIRE / October 14, 2024 / On Sept. 30, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed a major milestone with the full-scale fatigue testing of an MQ-9B Remotely Piloted Aircraft (RPA). The team completed the "second lifetime" of fatigue testing, which is equivalent to 80,000 operating hours and represents an important step in validating the design of the airframe system. The testing is part of the aircraft certification to NATO standard STANAG 4671, where the aircraft will ultimately be tested through three lifetimes, thereby proving the 40,000-hour lifetime of the airframe.
The full-scale fatigue test simulates the aircraft's design service through the application of repeated structural loading on the assembled airframe. The testing identifies any potential structural deficiencies ahead of fleet usage and assists in developing inspection and maintenance schedules for the airframe. The results of the test will be used as part of the documentation for certification and will form the basis for in-service inspections of structural components.
MQ-9B is GA-ASI's most advanced RPA and includes the SkyGuardian® and SeaGuardian® models as well as the new Protector RG Mk1 that is currently being delivered to the United Kingdom Royal Air Force (RAF).
"Full-scale fatigue testing is an integral part of validating the airframe design and a key input for the certification of the airframe prior to entering service," said Chris Dusseault, vice president of MQ-9B in Europe. "The completion of the fatigue test builds confidence for our MQ-9B customers that the SkyGuardian/SeaGuardian meets the stringent design rigor and is mature at Entry into Service."
The testing is the validation of years of design and analysis efforts. This is the second of three lifetimes of testing for the airframe. Two of the lifetimes simulate the operation of an aircraft under normal conditions, and the third has intentional damage inflicted on the airframe's critical components to demonstrate its resistance to operational damage that may occur over the lifetime of the air vehicle.
Testing was conducted from Jan. 31, 2024, through Sept. 30, 2024, at Wichita State University's National Institute for Aviation Research in Wichita, Kansas. The airframe tested is a production airframe purpose-built to support the test campaign.
In addition to the RAF, contracts have been signed for MQ-9B with Belgium, Canada, Japan, Taiwan and the U.S. Air Force in support of the Special Operations Command. The Japan Coast Guard is currently operating the SeaGuardian for maritime operations, and the Japan Maritime Self-Defense Force (JMSDF) selected SeaGuardian for its Medium-Altitude, Long-Endurance (MALE) RPA System Trial Operation Project.
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.
For more information, visit www.ga-asi.com.
Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.
Contact Information
GA-ASI Media Relations
asi-mediarelations@ga-asi.com
SOURCE: General Atomics Aeronautical Systems, Inc.
View the original press release on newswire.com.
General Atomics
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
Polaris Renewable Energy Successfully Settles USD 175 Million Bond Issue4.12.2024 16:05:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 4, 2024 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announces that it has successfully settled a previously announced private placement of USD 175 million senior secured green bonds. The bonds will have a tenor of five years and a fixed coupon rate of 9.5% percent per annum, with interest payable in semi-annual instalments. Furthermore, the Green Bond will include a tap feature, allowing for access to an additional USD $50 million in funding for potential future uses. The bond issue is rated BB- by S&P Global Ratings and is issued under the Company's green finance framework with second-party opinion from Morningstar Sustainalytics. Marc Murnaghan, Chief Executive Officer of Polaris comments: "We are very pleased to successfully settle this inaugural bond issue with strong interest from a wide set of international investors. The bond optimizes the Company's capital structure and secures financing for further growth and incre
Autobrains and JOYNEXT Revolutionize Smart Camera Solution Powered by Autobrains’ Affordable Safety ADAS Software4.12.2024 04:00:00 CET | Press release
Driving the Future of Safety: Cost-Effective, AI-Powered ADAS Solutions for Global OEMs MUNICH, GERMANY | DRESDEN, GERMANY | TEL AVIV, ISRAEL / ACCESSWIRE / December 4, 2024 / Autobrains, a leader in automotive artificial intelligence (AI), has joined forces with JOYNEXT, a global automotive Tier-1 supplier and development partner to renowned car manufacturers for over 20 years, to offer their groundbreaking Smart Camera ADAS solution. The camera hardware and optimized control software, provided by JOYNEXT, is powered by Autobrains' Affordable Safety ADAS software. The single-box Smart Camera solution, optimized for cost-effective Advanced Driver Assistance Systems (ADAS), was designed to meet the evolving needs of global Original Equipment Manufacturers (OEMs). This compact system simplifies integration, reduces costs, and ensures regulatory compliance without sacrificing performance. With ever increasing global regulations, smart cameras are a must-have in new build vehicles. The joi
IXOPAY and Aperia Compliance Merge to Extend Advanced Payment Data Security to Merchant Acquirers and Merchants of All Sizes, Worldwide4.12.2024 00:00:00 CET | Press release
Merger combines IXOPAY's enterprise-grade capabilities in payment orchestration and tokenization with Aperia Compliance's PCI DSS Level 3 and 4 solutions. TULSA, OKLAHOMA / ACCESSWIRE / December 4, 2024 / IXOPAY, a leading payments technology provider handling more than $35 billion in payment volume through its enterprise-grade payment orchestration platform, announced today that it has merged with Aperia Compliance, a subsidiary of Aperia Solutions and a leading firm in Payment Card Industry Data Security Standard (PCI DSS) data validation and risk management. Serving more than 100 merchant acquirers, Aperia Compliance will operate as "Aperia Compliance, an IXOPAY company." IXOPAY offers enterprise-grade PCI DSS Level 1 and 2 solutions powered by advanced tokenization. Paired with Aperia Compliance's robust PCI DSS Level 3 and 4 solutions-including PCI Apply 4.0 and the new 6.4.3 product-the combined offering aims to deliver a scalable, end-to-end solution enabling merchants, independ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom